Ebola Attestation, Early Flu, and the First-Ever Drug for Limb-Girdle Dystrophy

Today's roundup covers a new public-health enforcement measure tied to the ongoing Bundibugyo Ebola outbreak, an early European respiratory season, a landmark regulatory moment for a form of muscular dystrophy that has never had an approved treatment, and a continuing international alert for a rare hantavirus strain.

Ebola DRC: US Travel Attestation Rule Takes Effect Today

A new United States Centers for Disease Control and Prevention (CDC) order took effect today requiring every passenger boarding an international flight bound for the United States to sign a written attestation confirming they have not been physically present in the Democratic Republic of the Congo (DRC) in the 21 days before departure. Airlines are prohibited from boarding anyone who does not provide the attestation; knowingly providing false information may result in criminal penalties under US federal law.

The rule reflects the scale and duration of the 2026 Bundibugyo-strain Ebola outbreak, which the WHO Director-General declared a Public Health Emergency of International Concern (PHEIC) on 17 May 2026. The Bundibugyo strain is distinct from the better-known Zaire strain and has no licensed vaccine; clinical vaccine candidates are under investigation. As of early September 2026, WHO-compiled figures placed confirmed cases above 6,500 and confirmed deaths above 3,100 across DRC and Uganda combined — making this the second-largest Ebola outbreak on record. No confirmed cases have been reported in the United States.

The attestation applies to transit: passengers who connect through a DRC airport without leaving the aircraft are still considered to have been present in the country. Airline industry groups had urged the CDC to exempt crew members, US military personnel, and jumpseat travellers, noting that fewer than 25,000 of the 130 million air passengers screened at US borders in 2025 had any DRC connection. The CDC had not publicly modified the rule in response as of today. For travellers in Cyprus and the broader eastern Mediterranean, the requirement applies to any itinerary whose connection leads to a US-bound flight, regardless of where the connecting airport is located.

Andes Hantavirus: International Alert Continues After Cruise Ship Cluster

The Andes virus — the only known hantavirus capable of spreading directly from person to person — was confirmed in an outbreak aboard the Dutch-flagged expedition cruise ship MV Hondius in May 2026. As of the most recent ECDC and WHO reporting, 13 cases had been confirmed or classified as probable, including three deaths. Cases spread beyond the vessel: a crew member repatriated to the Netherlands and a passenger who disembarked in Saint Helena subsequently tested positive.

ECDC classified the event as a multi-country outbreak and initiated contact-tracing guidance. Andes virus causes a severe cardiopulmonary syndrome; there is no licensed vaccine and no specific antiviral treatment. Unlike most hantaviruses — which are contracted by inhaling rodent excreta — Andes virus can pass between people in close respiratory contact, though WHO characterises this mode of transmission as uncommon. Authorities continue to advise that overall public risk outside affected groups remains low. Passengers who travelled on affected Southern Ocean itineraries in April–May 2026 and develop respiratory or flu-like symptoms are advised to seek medical assessment and disclose their travel history.

Limb-Girdle Muscular Dystrophy: FDA Decision on BBP-418 Approaches

The United States Food and Drug Administration has a Prescription Drug User Fee Act (PDUFA) target decision date of 27 November 2026 for BBP-418, an oral investigational therapy developed by BridgeBio Pharma for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). No therapy is currently authorised for any form of limb-girdle muscular dystrophy, making this one of the most significant upcoming decisions in rare neuromuscular disease in years.

LGMD2I/R9 is caused by mutations in the FKRP gene, which encodes a protein required for normal glycosylation of the dystrophin-glycoprotein complex in muscle membranes. BBP-418 provides a metabolic precursor that boosts this glycosylation pathway, slowing the muscle-fibre breakdown that characterises the disease. The FDA accepted the new drug application (NDA) with Priority Review and indicated it does not plan to hold an advisory committee meeting before the decision. The Phase 3 FORTIFY trial enrolled adults with genetically confirmed LGMD2I/R9; independent analysts have placed the probability of approval above 90% based on its results. If approved, BBP-418 would be the first authorised therapy for any LGMD form. The FKRP mutation is more prevalent in Northern European populations, and patient advocacy groups across Europe are watching the US outcome as a leading indicator of possible EMA review timelines.

Europe's Influenza Season: Early Rise Detected in Northern Europe

Influenza activity is rising earlier than seasonal norms in parts of Northern Europe. The UK Health Security Agency's week 44 surveillance report (published 29 October) recorded GP swabbing positivity for influenza in England at 11.0%, up from 7.8% the previous week — a steeper week-on-week increase than at the same point in the 2024–25 season. Respiratory syncytial virus (RSV) activity remains low at 0.6%, consistent with Iceland's health directorate, which reported no RSV detected in the country through week 43.

Historical patterns suggest that Northern European influenza signals typically reach Mediterranean countries, including Cyprus and Greece, within two to four weeks. The European Medicines Agency confirmed earlier this year that 2026–27 influenza vaccines include updated A(H1N1)pdm09 and A(H3N2) components aligned to currently circulating strains. Health authorities across the EU/EEA recommend annual vaccination, particularly for adults over 60, people with chronic conditions, healthcare workers, and pregnant women. Vaccination before community transmission peaks is the most effective personal preventive measure available.

AI in Clinical Diagnosis: Automation Bias Persists Despite Training, NEJM AI Finds

A study published in the November 2026 issue of NEJM AI examined whether structured AI literacy training reduced automation bias in physicians using large language model (LLM) diagnostic decision-support tools. It found that trained physicians still deferred to incorrect LLM diagnoses at a meaningfully higher rate than untrained controls — reducing, rather than improving, overall diagnostic accuracy when the AI suggested the wrong answer.

The researchers argue that AI literacy curricula designed to improve appropriate LLM use may be insufficient if they address awareness of AI fallibility without also addressing the psychological tendency to defer to algorithmic outputs under cognitive load. A follow-up letter in the same issue described the findings as a call for revised training frameworks rather than a reason to avoid diagnostic AI altogether. This is an early, single-center observational study; its conclusions await replication in larger, multicenter settings before policy recommendations can be drawn. For health systems in the eastern Mediterranean — where specialist shortages can place greater reliance on clinical decision tools — the findings argue for structural oversight mechanisms to sit alongside any AI co-pilot deployment.

---

This roundup is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to a treatment, vaccination, or medication plan.